CHRONIC ACTINOMYCES NEUII ENDOPHTHALMITIS POSTCATARACT SURGERY TREATED WITH INTRAVENOUS AND INTRAMUSCULAR ANTIBIOTICS AND INTRAOCULAR LENS EXPLANTATION: CASE REPORT AND REVIEW OF THE LITERATURE.

Retin Cases Brief RepSep 1, 2026
Case ReportOphthalmologyOpen access

Carol Tadrous, Nadine Cheffi, Rishi B Gupta et al.

✦ AI-curated · Sources linked

Case in brief

A 77-year-old man developed chronic endophthalmitis due to Actinomyces neuii following cataract surgery, presenting with recurrent anterior uveitis and cystoid macular edema. Despite multiple intravitreal antibiotics and vitrectomies, inflammation persisted. Treatment with intravenous and intramuscular penicillin, along with intraocular lens explantation, led to sustained resolution of inflammation, although visual acuity remained limited due to secondary complications.

Diagnostic / clinical pearl

This case underscores the necessity of systemic antibiotic therapy and interdisciplinary collaboration in managing chronic postoperative endophthalmitis caused by atypical pathogens.

Source

PubMed · PMID 42328866Free full text on PubMed Central

Published in Retin Cases Brief Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.